全文获取类型
收费全文 | 2852篇 |
免费 | 256篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 76篇 |
妇产科学 | 24篇 |
基础医学 | 501篇 |
口腔科学 | 33篇 |
临床医学 | 414篇 |
内科学 | 442篇 |
皮肤病学 | 25篇 |
神经病学 | 145篇 |
特种医学 | 203篇 |
外科学 | 463篇 |
综合类 | 90篇 |
预防医学 | 234篇 |
眼科学 | 10篇 |
药学 | 189篇 |
中国医学 | 3篇 |
肿瘤学 | 234篇 |
出版年
2021年 | 34篇 |
2020年 | 28篇 |
2019年 | 42篇 |
2018年 | 64篇 |
2017年 | 38篇 |
2016年 | 28篇 |
2015年 | 54篇 |
2014年 | 73篇 |
2013年 | 91篇 |
2012年 | 195篇 |
2011年 | 195篇 |
2010年 | 99篇 |
2009年 | 88篇 |
2008年 | 130篇 |
2007年 | 149篇 |
2006年 | 128篇 |
2005年 | 131篇 |
2004年 | 120篇 |
2003年 | 112篇 |
2002年 | 104篇 |
2001年 | 77篇 |
2000年 | 76篇 |
1999年 | 70篇 |
1998年 | 34篇 |
1997年 | 35篇 |
1996年 | 25篇 |
1995年 | 24篇 |
1994年 | 22篇 |
1993年 | 14篇 |
1992年 | 70篇 |
1991年 | 49篇 |
1990年 | 48篇 |
1989年 | 51篇 |
1988年 | 41篇 |
1987年 | 57篇 |
1986年 | 37篇 |
1985年 | 45篇 |
1984年 | 36篇 |
1983年 | 27篇 |
1982年 | 24篇 |
1981年 | 21篇 |
1979年 | 27篇 |
1978年 | 26篇 |
1976年 | 20篇 |
1975年 | 26篇 |
1974年 | 30篇 |
1973年 | 23篇 |
1972年 | 14篇 |
1969年 | 14篇 |
1968年 | 17篇 |
排序方式: 共有3111条查询结果,搜索用时 15 毫秒
1.
Amanda Bolderston Jackie Middleton Cynthia Palmaria Susan Cauti Susan Fawcett 《Journal of Medical Imaging and Radiation Sciences》2021,52(2):160-163
Lesbian, gay, bisexual, transgender, queer and two-spirit plus (LGBTQ2S+) people have distinct healthcare needs that may be unaddressed in many undergraduate healthcare curricula. The Radiation Therapy Program (RADTH) at the University of Alberta underwent a review of the three-year didactic curriculum using an online survey. The survey sought to ascertain if, where and how topics related to LGBTQ2S + healthcare are taught. Results indicated that out of 10 RADTH program faculty respondents, three teach related topics. The total time dedicated within the three-year curriculum was approximately three and a half hours. Other findings showed that faculty are interested in receiving more education in this area and would favour discussions about how to incorporate these themes into appropriate courses. This preliminary investigation demonstrated that there has been some initial work in this area, but there is more to be done. 相似文献
2.
3.
Mehdi Kordi Jonathan Folland Stuart Goodall Nicos Haralabidis Tom Maden-Wilkinson Tejal Sarika Patel Jonathan Leeder Paul Barratt Glyn Howatson 《Scandinavian journal of medicine & science in sports》2020,30(2):227-237
Mechanical peak power output (PPO) is a determinant of performance in sprint cycling. The purpose of this study was to examine the relationship between PPO and putative physiological determinants of PPO in elite cyclists, and to compare sprint performance between elite sprint and endurance cyclists. Thirty-five elite cyclists (18 endurance; 17 sprint) performed duplicate sprint cycling laboratory tests to establish PPO and its mechanical components. Quadriceps femoris (QVOL) and hamstring muscle volume (HAMVOL) were assessed with MRI, vastus lateralis pennation angle (PθVL) and fascicle length (FLVL) were determined with ultrasound imaging, and neuromuscular activation of three muscles was assessed using EMG at PPO during sprint cycling. For the whole cohort, there was a wide variability in PPO (range 775-2025 W) with very large, positive, bivariate relationships between PPO and QVOL (r = .87), HAMVOL (r = .71), and PθVL (r = .81). Step-wise multiple regression analysis revealed that 87% of the variability in PPO between cyclists was explained by two variables QVOL (76%) and PθVL (11%). The sprint cyclists had greater PPO (+61%; P < .001 vs endurance), larger QVOL (P < .001), and BFVOL (P < .001) as well as more pennate vastus lateralis muscles (P < .001). These findings emphasize the importance of quadriceps muscle morphology for sprint cycling events. 相似文献
4.
5.
6.
7.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
8.
Nadia J. Kershaw Artem Laktyushin Nicos A. Nicola 《Growth factors (Chur, Switzerland)》2014,32(1):1-10
AbstractSOCS3 (suppressor of cytokine signaling 3) inhibits the intracellular signaling cascade initiated by exposure of cells to cytokines. SOCS3 regulates signaling via two distinct mechanisms: directly inhibiting the catalytic activity of Janus kinases (JAKs) that initiate the intracellular signaling cascade and catalysing the ubiquitination of signaling components by recruiting components of an E3 ubiquitin ligase complex. Here we investigate the latter mode-of-action biochemically by reconstructing a SOCS3-based E3 ubiquitin ligase complex in vitro using fully purified, recombinant components and examining its ability to promote the ubiquitination of molecules involved in the cytokine signaling cascade. We show that SOCS3 is an active substrate recruitment module for a Cullin5-based E3 ligase and have defined the core protein components required for ubiquitination. SOCS3-induced polyubiquitination was rapid and could proceed through a number of different ubiquitin lysines. SOCS3 catalyzed the ubiquitination of both the IL-6 receptor common chain (gp130) and JAK2. 相似文献
9.
High‐Resolution HLA Typing for Sensitized Patients: Advances in Medicine and Science Require Us to Challenge Existing Paradigms 下载免费PDF全文
R. J. Duquesnoy H. M. Gebel E. S. Woodle P. Nickerson L. A. Baxter‐Lowe R. A. Bray F. H. J. Claas D. D. Eckels J. J. Friedewald S. V. Fuggle J. A. Gerlach J. J. Fung M. Kamoun D. Middleton R. Shapiro A. R. Tambur C. J. Taylor K. Tinckam A. Zeevi 《American journal of transplantation》2015,15(10):2780-2781
10.
Difference in outcomes after antibody‐mediated rejection between abo‐incompatible and positive cross‐match transplantations 下载免费PDF全文
Lionel Couzi Miriam Manook Ranmith Perera Olivia Shaw Zubir Ahmed Nicos Kessaris Anthony Dorling Nizam Mamode 《Transplant international》2015,28(10):1205-1215
Graft survival seems to be worse in positive cross‐match (HLAi) than in ABO‐incompatible (ABOi) transplantation. However, it is not entirely clear why these differences exist. Sixty‐nine ABOi, 27 HLAi and 10 combined ABOi+HLAi patients were included in this retrospective study, to determine whether the frequency, severity and the outcome of active antibody‐mediated rejection (AMR) were different. Five‐year death‐censored graft survival was better in ABOi than in HLAi and ABOi+HLAi patients (99%, 69% and 64%, respectively, P = 0.0002). Features of AMR were found in 38%, 95% and 100% of ABOi, HLAi and ABOi+HLAi patients that had a biopsy, respectively (P = 0.0001 and P = 0.001). After active AMR, a declining eGFR and graft loss were observed more frequently in HLAi and HLAi+ABOi than in ABOi patients. The poorer prognosis after AMR in HLAi and ABOi+HLAi transplantations was not explained by a higher severity of histological lesions or by a less aggressive treatment. In conclusion, ABOi transplantation offers better results than HLAi transplantation, partly because AMR occurs less frequently but also because outcome after AMR is distinctly better. HLAi and combined ABOi+HLAi transplantations appear to have the same outcome, suggesting there is no synergistic effect between anti‐A/B and anti‐HLA antibodies. 相似文献